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Abstract
Metastatic melanoma has poor prognosis and is refractory to most conventional chemotherapies. The alkylating agent
temozolomide (TMZ) is commonly used in treating melanoma but has a disappointing response rate. Agents that can act
cooperatively with TMZ and improve its efficacy are thus highly sought after. The BH3 mimetic ABT-737, which can induce
apoptosis by targeting pro-survival Bcl-2 family members, has been found to enhance the efficacy of many conventional
chemotherapeutic agents in multiple cancers. We found that combining TMZ and ABT-737 induced strong synergistic
apoptosis in multiple human melanoma cell lines. When the drugs were used in combination in a mouse xenograft model,
they drastically reduced tumor growth at concentrations where each individual drug had no significant effect. We found
that TMZ treatment elevated p53 levels, and that the pro-apoptotic protein Noxa was elevated in TMZ/ABT-737 treated
cells. Experiments with shRNA demonstrated that the synergistic effect of TMZ and ABT-737 was largely dependent on
Noxa. Experiments with nutlin-3, a p53 inducer, demonstrated that p53 induction was sufficient for synergistic cell death
with ABT-737 in a Noxa-dependent fashion. However, p53 was not necessary for TMZ/ABT-737 synergy as demonstrated by
a p53-null line, indicating that TMZ and ABT-737 together induce Noxa in a p53-independent fashion. These results
demonstrate that targeting anti-apoptotic Bcl-2 members is a promising method for treating metastatic melanoma, and
that clinical trials with TMZ and Bcl-2 inhibitors are warranted.
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Introduction
The incidence of metastatic melanoma has increased rapidly in
recent decades, but unfortunately there has been little improve-
ment in therapeutic efficacy [1]. Dacarbazine is the standard first-
line treatment for advanced melanoma, but its response rate is
poor, averaging around 15% with no improvement in survival
duration [1,2]. Temozolomide (TMZ), which spontaneously
decomposes into the active metabolite of dacarbazine [3], is
frequently used ‘‘off-label’’ in place of dacarbazine because of its
ease of use and bioavailability; however, its response rate is equally
poor. Chemotherapeutic agents that can be combined with TMZ
to increase its response rate are therefore highly sought after, as an
effective combination would have immediate clinical application.
Agents that have been combined with TMZ in clinical trials
include arsenic trioxide and ascorbic acid [4], cisplatin [5], and
thalidomide [6]; unfortunately, they were found to have no
benefit.
Whether and to what degree TMZ induces apoptosis in
melanoma cells is a subject of debate. Some studies have shown
that clinically relevant doses of TMZ do not induce significant
levels of apoptosis in melanoma cells in vitro, potentially explaining
its poor clinical response rate [7,8]. However, recently, Naumann
and coworkers found that apoptosis is the major mode of death for
melanoma cells exposed to TMZ, but that it requires time for
double-stranded DNA breaks to occur, and thus apoptosis is not
observed with short treatment times (72 h or less) [9]. Enhancing
the apoptotic potential of TMZ, for example by triggering
apoptosis under situations in which cell cycle arrest would
predominate, is a promising means of enhancing the efficacy of
TMZ in melanoma patients.
Many cancers, particularly melanomas, are resistant to
apoptosis by upregulation of anti-apoptotic Bcl-2 family members.
As a means of overcoming this resistance, agents that mimic pro-
apoptotic BH3-only proteins, such as ABT-737, have been
developed. ABT-737 potently inhibits anti-apoptotic Bcl-2 family
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the BH3-only protein Bad [10]. It has been shown to enhance the
activity of a variety of cytotoxic drugs, and is thus an excellent
candidate for rational drug combinations [11]. We previously
found that resistance to ABT-737 in melanoma cells is mediated
by the anti-apoptotic Bcl-2 member Mcl-1, which ABT-737 does
not inhibit [12]. The induction of Noxa, which selectively inhibits
Mcl-1, via the protease inhibitors MG-132 [12] or Bortezomib
(unpublished data) is able to overcome this resistance. Knockdown
of Mcl-1 results in increased sensitivity to ABT-737, while
knockdown of Noxa protects cells from the killing induced by
the combination of the two drugs [12]. Numerous additional in
vitro studies for both melanoma and other cancer cells have shown
that the Mcl-1/Noxa ratio is critical for determining resistance or
sensitivity to ABT-737 [13,14,15,16,17,18].
In the present study, we tested the BH3-only mimetic ABT-737
in combination with the commonly used alkylating agent TMZ,
and found strong synergistic induction of apoptosis in several
melanoma cell lines within a short time period, and a significant
reduction in tumor growth in a mouse xenograft model. We found
that Noxa was induced by the combination treatment, but not by
single drug treatments, and that knockdown of Noxa almost
completely abrogated cell death induced by the combination.
Although induction of p53 was sufficient to cause Noxa-mediated
cell death, it was not necessary, indicating that the ABT-737/
TMZ combination induces Noxa through a p53-independent
pathway.
Results
ABT-737 synergistically induces apoptosis in melanoma
cells when combined with temozolomide
MTS experiments (Fig. 1A and data not shown) showed that
TMZ alone reduced total viability, and that this was reduced
further in the presence of ABT-737. IC50 values for each drug at
72 h are listed in Table S1, and time-course data are shown in Fig.
S1. Median effect analysis showed that the combination was
synergistic over a wide range of drug concentrations at 72 h (Fig.
S2), with combination index (CI) values ranging from 0.1 to 0.4 for
1205Lu and 0.3 to 0.8 for A375. The visual appearance of the cells
(Fig. 1B) made it clear that the combination of ABT-737 and TMZ
induced cell death whereas TMZ alone primarily reduced cell
proliferation by 72 h. To quantify the level of apoptosis in
combination treatments compared to single agent treatments, we
performed Annexin V assays after cells were exposed to 400 mM
TMZ alone, 3.3 mM ABT-737 alone, or both agents in
combination for 72 h for several cell lines. Figure 1C shows that
ABT-737 and TMZ alone induced little cell death above the
controls treated with vehicle. For combination treatments
however, high levels of cell death were found for all cell lines,
indicating a synergistic effect between TMZ and ABT-737.
TMZ and ABT-737 combination treatment induces Noxa
and p53 expression
Western blotting (Fig. 2) for 1205Lu and A375 demonstrated
elevated levels of Noxa (roughly 6- and 2-fold, respectively) in cells
treated with a combination of TMZ and ABT-737, though Noxa
levels in cells treated only with TMZ remained unchanged. Mcl-1
levels were unchanged, resulting in a highly increased Noxa/Mcl-
1 ratio in the combination group. Additionally, TMZ treatment
greatly increased the levels of p53 (roughly 3- and 5-fold for
1205Lu and A375, respectively), which is known to induce pro-
apoptotic Bcl-2 family members. However, levels of PUMA, Bid,
and Bax were unchanged, and there was no indication of Bid
truncation (tBid). These results imply that the synergy of TMZ and
ABT-737 may be mediated through either increased Noxa or p53
levels, but that other pro-apoptotic Bcl-2 family members tested
are unlikely to play a role.
ABT-737 synergy with TMZ is Noxa-dependent
To test the involvement of Noxa in TMZ and ABT-737
synergy, we created 1205Lu and A375 cell lines stably expressing
short hairpin RNA (shRNA) against Noxa (shNoxa). Western
blotting confirmed the knockdown of Noxa in these lines (Fig. 3C,
D). Annexin V experiments (Fig. 3A, B) showed that the synergistic
killing effect of TMZ and ABT-737 was almost completely
abrogated in shNoxa lines, indicating that Noxa is necessary for
the synergy. Western blots (Fig. 3C, D) show greatly reduced
PARP cleavage in shNoxa cells compared to shControl cells,
corroborating the Annexin V assays and showing that Noxa is
necessary for apoptosis in the combination treatment.
Induction of p53 is sufficient, but not necessary, to
induce synergistic cell death with ABT-737 in melanoma
cell lines
To test if p53 induction alone was sufficient to cause synergistic
apoptosis with ABT-737, we tested the compound nutlin-3, which
increases p53 levels by inhibiting p53 degradation through MDM2-
mediated ubiquitination of p53 [19]. We performed Annexin V
assays for A375 and 1205Lu cells treated with the drugs for 72 h.
Fig. 4A shows that nutlin-3 and ABT-737 induced little apoptosis at
4 mM and 3.3 mM, respectively, but both drugs together induced
apoptosis in roughly half of the cells. The visual appearance of cells
(not shown) indicated that nutlin-3 alone mostly reduced cell
proliferation, whereas cell death was most commonwhen combined
with ABT-737, a phenomenon highly similar to TMZ. Immuno-
blots of lysates from the Annexin experiments (Fig. 4C) show that
Noxa was increased in nutlin-3-treated cells (roughly 8-fold), but
increased more so in the combination treatments (roughly 20-fold).
When shNoxa lines were treated with the combination of nutlin-3
and ABT-737 (Fig. 4B), apoptosis was almost completely abrogated,
similar to TMZ combination treatments.
To further test whether p53 induction is necessary for the
synergistic effect of TMZ and ABT-737, we used the cell line
RPMI-7951, which is homozygous for a p53 nonsense mutation at
S166 [20]. MTS and Annexin V assays (Fig. 5B, C) showed that
RPMI-7951 cells were unaffected by nutlin-3 as expected.
However, surprisingly, RPMI-7951 cells underwent synergistic
cell death when treated with TMZ and ABT-737 (Fig. 5A, C).
Noxa was induced in TMZ/ABT-737 combination treatments by
over 3-fold compared to the control (Fig. 5D), similar to p53 wild-
type cell lines. We were unable to detect any p53 in RPMI-7951
cells (Fig. 5E), even when treated with TMZ or nutlin-3, indicating
that the p53 message was either degraded through nonsense-
mediated mRNA decay, or that the truncated protein was quickly
degraded. We therefore regard this cell line as p53-null. In spite of
this, we found that it was sensitive to TMZ and ABT-737
combination treatments. These results demonstrate that induction
of Noxa is necessary to cause synergy with ABT-737, and that
while induction of p53 is sufficient for synergistic cell death
(mediated through Noxa), it is not necessary.
TMZ and ABT-737 reduce tumor growth in a mouse
xenograft model
We administered ABT-737, TMZ, or both drugs together in a
mousexenograftmodelwithA375 cellsinjectedsubcutaneouslyinto
eachflank.AsshowninFig.6,ABT-737andTMZtreatmentsalone
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(p=0.2570 and 0.3252, respectively). However, the combination
treatment highly significantly slowed the rate of tumor growth
compared to the control (p=0.0005) and to the individual drug
treatment groups (p=0.0037 and 0.0276 vs. ABT-737 and TMZ,
respectively). Notably, the mice that received the drug combination
appeared normal without weight loss (data not shown) or any other
noticeable side effects. These results imply that the combination of
ABT-737 and TMZ can reduce the growth of melanoma tumors in
vivo, and that the drug combination is likely to be safe.
Discussion
Metastatic melanoma is responsible for roughly 80% of all skin
cancer deaths and has a 5-year survival rate of only 14%, even
with TMZ as a standard treatment [21]. Thus, new treatment
options that can be quickly moved to clinic are desperately needed.
Melanomas are notoriously resistant to apoptosis induction by
TMZ and other chemotherapeutic agents [22]. Although much
attention has been focused on DNA damage repair mechanisms in
mediating this resistance [23], targeting apoptotic pathways
directly is a potential means of improving the poor clinical
efficacy of TMZ.
To enhance the ability of TMZ to induce apoptosis, we
combined it with the BH3-only mimetic ABT-737. Our results
with TMZ alone are consistent with those of previous studies
showing that TMZ primarily reduces the rate of cell growth but
induces little apoptosis within short time frames, even though we
used a relatively high dose [7,8,9]. However, when used in
combination with ABT-737, TMZ strongly induced apoptosis in
multiple cell lines by 72 h, in some cases resulting in nearly
complete cell death. We also found that the combination was
effective in melanoma cells carrying either BRAF or NRAS
activating mutations, since A375, 1205Lu, and WM239a lines
each have BRAF
V600 mutations, while WM852c and SBCL2 lines
have NRAS
Q61 mutations. We also found two cell lines, SK-Mel
28 and 451Lu, with high levels of methylguanine methyltransfer-
ase (MGMT), an enzyme that directly repairs methylguanine
adducts and is implicated in TMZ resistance [24]. These lines
were completely resistant to the effects of TMZ, and hence also
resistant to the drug combination (data not shown). However, the
addition of an MGMT inhibitor, O
6-benzylguanine, restored
TMZ sensitivity and the synergistic effect of the TMZ/ABT-737
drug combination (data not shown), indicating that MGMT does
not affect the mechanism of drug synergy.
We found strong induction of p53 with TMZ treatment, and
experiments with the p53-inducing agent nutlin-3 support the idea
that induction of p53 can cause synergistic killing when combined
with ABT-737 in some cell lines. The effects of nutlin-3 on 1205Lu
and A375 melanoma cell lines, both alone and in combination
with ABT-737, were remarkably similar to those of TMZ. This
indicates that combining ABT-737 with agents that induce p53 is
also a promising strategy for treating p53 wild-type melanomas.
However, we found that RPMI-7951, a p53-null line, was sensitive
to TMZ/ABT-737 but not to nutlin-3/ABT-737, demonstrating
that p53 is not necessary for synergistic cell death induced by
TMZ and ABT-737. This result is consistent with previous studies
showing that p53 status is irrelevant to the effect of TMZ in
melanoma cells [9]. It also implies that combining ABT-737 with
TMZ may be a better strategy than inducing p53, since the former
should work regardless of p53 status.
The apoptotic pathway is regulated by Bcl-2 family members,
and high levels of the anti-apoptotic Bcl-2 members are implicated
in the resistance of cancer cells to apoptosis. ABT-737 promotes
apoptosis by serving as a BH3-only mimetic, counteracting the
increased levels of anti-apoptotic Bcl-2 members. Our previous
work has shown that melanoma cells are only slightly sensitive to
ABT-737 at high doses, and that this resistance is mediated
exclusively through Mcl-1 [12]. The inhibition of Mcl-1, either
directly or through the induction of proteins antagonizing Mcl-1,
should therefore greatly increase the cell killing ability of ABT-
737. Noxa, BID (in its truncated form, tBID), and PUMA are
known to sequester Mcl-1 and serve as pro-apoptotic molecules
[25]. BAX is a main mediator of mitochrondrial apoptosis, so
increased levels of BAX can potentially overcome sequestration by
Mcl-1. However, we found that TMZ alone failed to induce any of
these proteins significantly and consistently above levels seen in
multiple vehicle-treated cell lines. In contrast, in TMZ/ABT-737
combination-treated cells, there was a notable increase of Noxa in
multiple cell lines.
Experiments with shRNA against Noxa demonstrated that the
synergistic killing of TMZ and ABT-737 is mediated at least in part
through Noxa. Identical experiments using nutlin-3 in lieu of TMZ
showed that Noxa is increased by nutlin-3 and especially in the
combinationtreatments,andthatNoxaisalsonecessaryfornutlin-3/
ABT-737-mediated cell death in A375 cells, indicating that Noxa is
also the key downstream target of p53 induced by nutlin-3.
Additionally, we tested A375 cells in which BIM and PUMA were
knocked-down by shRNA. MTS assays using these cells treated with
TMZ/ABT-737 indicated that synergistic cell death is not mediated
throughtheseproteins(datanotshown).Wethereforeconcludedthat
Noxa is the main mediator of cell death induced by TMZ/ABT-737.
We also found that Noxa was increased upon TMZ/ABT-737
treatment in both the p53-null cells and wild-type p53 cells. The
combination of TMZ and ABT-737 must therefore cause p53-
independent Noxa induction. However, nutlin-3 treatment
increased Noxa only in wild-type p53 cells. These results suggest
that TMZ and nutlin-3 are inducing Noxa through different
mechanisms. Nutlin-3 alone induced Noxa, providing a simple
explanation for how it synergizes with ABT-737, but surprisingly,
TMZ alone did not. Instead, TMZ only induced Noxa when
combined with ABT-737, and did so even in the complete absence
of p53. So while nutlin-3 appears to be inducing Noxa through a
p53-dependent mechanism, TMZ must be doing so through a
p53-independent mechanism, one that operates only in the
presence of ABT-737. It is unclear at present what this mechanism
is, or why p53 induced by TMZ is insufficient to induce Noxa by
itself. Although there are many reports of p53-independent Noxa
induction, the mechanisms responsible are often undetermined. It
is known that Noxa can be induced via cMyc during proteasome
inhibition [26], and that E2F1 can induce Noxa along with other
BH3-only proteins [27]. However, we did not find elevated cMyc
levels in any of our treatment groups, and paradoxically, E2F1
levels were significantly decreased in TMZ and TMZ/ABT-737
treated cells (data not shown). The mechanism by which TMZ/
ABT-737 induces Noxa will require further study.
Results from our in vivo mouse model are consistent with our in
vitro data. The combination of TMZ and ABT-737 caused tumors
Figure 1. TMZ and ABT-737 cause strong, synergistic cell death in melanoma cell lines. (A) MTS assays of 1205Lu (top) and A375 (bottom)
cell lines treated with varying doses of TMZ with or without 3.3 mM ABT-737 for 96 h. (B) The visual appearance of cells (1006magnification) treated
with varying doses of TMZ with or without 1.1 mM ABT-737 for 72 h. TMZ treatment primarily reduced cell proliferation, while the combination
treatment caused cell death. (C) Annexin V assays for various cell lines treated with TMZ (400 mM) and ABT-737 (3.3 mM) for 72 h.
doi:10.1371/journal.pone.0024294.g001
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mice or to mice treated with either drug alone. The drugs used
individually were at doses where neither had a significant effect
compared to the control. Since the dose used for TMZ was
relatively low (15 mg/kg), these results imply that when combined
with ABT-737, clinically relevant doses of TMZ may cause tumor
shrinkage in human patients, not merely a reduction of growth.
Notably, there were no readily apparent adverse side effects such
weight loss, lethargy, or flaky skin as seen with Bortezomib
treatment (unpublished observation), indicating that the drug
combination is likely to be minimally toxic.
Our in vivo and in vitro data, plus the apparent safety of the drug
combination, imply that a combination of TMZ and ABT-737 (or
its oral form, ABT-263) is warranted for clinical trial. Melanoma is
an especially good candidate for treatment with this drug
combination, because TMZ is already in widespread use for
treating metastatic melanoma, providing an avenue for immediate
clinical benefit. Additionally, while melanomas have a surprisingly
low rate of p53 mutations (,10%) [28], our data indicate that the
drug combination should work irrespective of p53 status.
In conclusion, we found that TMZ and ABT-737 synergize to
promote cell death in multiple melanoma cell lines, and
dramatically reduce tumor growth in a mouse model even when
used at low doses. Our data indicate that this synergy occurs
through the p53-independent induction of Noxa, although p53-
dependent induction of Noxa through nutlin-3 produces a similar
effectand maybeeffectiveagainstp53wild-typetumors.Ourresults
show that combining TMZ with anti-apoptotic Bcl-2 inhibitors is a
promising method for treating melanomas, and that clinical trials
with TMZ and ABT-737-like compounds are warranted.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
experiments were approved by the Institutional Animal Care and
Use Committee of the University of Colorado Denver (protocol
number 88509(09)1E).
Reagents
Temozolomide (99% purity), nutlin-3, and O
6-benzylguanine
were obtained from Sigma-Aldrich (St. Louis, MO). ABT-737 was
kindly provided by Abbott Laboratories (Abbott Park, IL).
Cell lines and culture conditions
The following human melanoma cell lines were used: metastatic
cell lines A375, 1205Lu, SK-Mel 28, 451Lu, and RPMI-7951
were obtained from ATCC (Manassas, VA). Metastatic cell lines
WM852c and WM239a, and radial growth phase cell line SBCL2,
were kindly provided by Dr. Meenhard Herlyn (Wistar Institute,
Philadelphia, PA). Cells were maintained in RPMI1640 media
(Invitrogen, Grand Island, NY) with 10% fetal bovine serum
Figure 2. p53 and Noxa are increased in TMZ/ABT-737 treated cells. Immunoblots are of lysates from Annexin V experiments shown in
Fig. 1C with 72 h drug exposure. PARP cleavage indicates high levels of apoptosis in combination treated cells. TMZ treatment alone increases levels
of p53, but only the combination treatment increases Noxa. Other Bcl-2 family members tested remained unchanged. Relative ratios of Noxa and p53
to tubulin are shown below, with each value normalized to the control.
doi:10.1371/journal.pone.0024294.g002
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1205Lu, SK-Mel 28, 451Lu, and RPMI-7951 lines each have
BRAF
V600E mutations. WM239a has BRAF
V600D, WM852c has
NRAS
Q61R, and SBCL2 has the NRAS
Q61K mutation. Cell lines with
a BRAF mutation do not have common mutations in NRAS
(exons 1 or 2), and lines with NRAS mutations do not have BRAF
mutations (exons 11 or 15). RPMI-7951 is homozygous for a
nonsense mutation in the p53 gene at codon 166 [20]. All other
cell lines used in Annexin V assays are p53 wild-type. Cell lines
SK-Mel 28 and 451Lu have high levels of methylguanine
methyltransferase (MGMT), while A375, WM852c, and SCBL2
have 2-3 fold lower levels. We could not detect MGMT in 1205Lu
or WM239a lines. None of the cell lines used in this study have
been previously reported to be deficient in mismatch repair.
Measurement of cell proliferation and apoptosis
The Cell Titer 96TM Aqueous One solution cell proliferation
assay (MTS assay; Promega Corp., Madison, WI) was used to
quantify cell viability. Assays were performed according to the
manufacturer’s instructions. Control experiments in which TMZ
and ABT-737 were added to wells without cells demonstrated that
the drugs do not react with the MTS reagent or otherwise interfere
with the assay. The Annexin V-FITC Apoptosis Detection Kit
(BD Biosciences, San Jose, CA) was used to quantify apoptosis
according to the manufacturer’s protocol. Cells were analyzed by
flow cytometry using a Beckman Coulter FC500 with CXP
software (Hialeah, FL) in the University of Colorado Cancer
Center Flow Cytometry Core.
Creation of short hairpin RNA transduced cell lines
Short hairpin RNA (shRNA) expressing lines against various
Bcl-2 family members, or scrambled control, were constructed
using shRNA Lentiviral Particles from Santa Cruz Biotechnology
(Santa Cruz, CA) according to the manufacturer’s instructions
with slight modification. Briefly, cells were seeded in 12-well plates
for 24 h at concentrations sufficient to reach 50% confluency. The
media was removed from each well and replaced with 1 ml of
chilled polybrene working solution (5 mg/ml in RPMI1640
medium) and incubated at RT for 5 min. The solution was
removed and replaced with 1 ml of chilled polybrene working
solution with up to 20 ml of viral particle and incubated at 37uC.
The solution was then removed 24 h later, cells were rinsed once
with fresh media, and then 1 ml of fresh media was added. Cells
were grown until sufficient numbers were available for selection.
Transduced cells were selected by supplementing the media with
puromycin (1–4 mg/ml) for several days, replacing the medium
with fresh puromycin-containing medium every 3–4 days until
resistant colonies could be identified. Knockdown of genes of
interest was measured by immunoblotting of cell lysates.
Immunoblot
Cells, both floating and adherent, were harvested with 1x
Laemmli Sample Buffer (Bio-Rad, Hercules, CA). Samples were
used in the standard western blot analysis protocol as described
previously [29]. Blots were developed with HRP substrate
(SuperSignal West Pico or Femto solutions, Pierce, Rockford,
IL) for 5 min at room temperature, and analyzed using a Chemi-
Figure 3. Synergy between TMZ and ABT-737 is Noxa-dependent. Annexin V assays of 1205Lu (A) and A375 (B) shNoxa and shControl cells
treated with or without 400 mM TMZ and 3.3 mM ABT-737 for 72 h. Immunoblots of cell lysates from Annexin V experiments for 1205Lu (C) and A375
(D) cells show Noxa knockdown and lack of PARP cleavage for shNoxa lines, while high levels of Noxa exist in combination-treated shControl lines.
doi:10.1371/journal.pone.0024294.g003
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and A375 cells treated with or without 4 mM nutlin-3 and 3.3 mM ABT-737. (B) A375 shNoxa and shControl cells treated with or without 4 mM nutlin-3
and 3.3 mM ABT-737. (C) Immunoblots of lysates from the Annexin V experiments shown in B show Noxa knockdown and lack of PARP cleavage in
the shNoxa line. Relative ratios of Noxa to tubulin are shown below, with each value normalized to the control.
doi:10.1371/journal.pone.0024294.g004
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following antibodies were used at suggested dilutions from the
manufacturers: Bax, PARP, MGMT, and a/b Tubulin were from
Cell Signaling Technology (Danvers, MA); Noxa was from EMD
Biosciences, Inc. (San Diego, CA); Mcl-1 was from BD Biosciences
(San Jose, CA); Bcl-2 was from Dako (Glostrup, Denmark); p53
was from Santa Cruz Biotechnology; PUMA was from Sigma; and
HRP-conjugated goat anti-mouse and anti-rabbit antibodies were
from Jackson Immuno-Research (West Grove, PA). Immunoblots
were typically performed 2–3 times for multiple cell lines, and
representative examples are shown. Immunoblot data was
quantified using Quantity One software (Bio-Rad).
Mouse xenograft model
Female NCRNU nude mice, aged 5–6 weeks, were purchased
from Taconic (Hudson, NY). Each mouse was subcutaneously
injected on each flank with 2 million A375 cells in a 100 ml volume
consisting of 50% BD Matrigel Matrix (BD Biosciences) prepared
according to the manufacturer’s protocol. Drug treatments began
after tumors reached approximately 100 mm
3, at around 1 week.
Mice were randomly divided into four treatment groups consisting
of 10 tumors each group: 1) vehicle only, 2) ABT-737 only, 3) TMZ
only, 4) TMZ plus ABT-737. TMZ and ABT-737 were adminis-
tered at 15 mg/kg and 100 mg/kg, respectively. All mice received
either the drug or vehicle for both drugs. ABT-737 was prepared
fresh every 7 days by dissolving it in vehicleconsisting of 65%D5W,
30% propylene glycol, 5% Tween-80, pH 1.0. The pH was raised
to ,3.5 after the drug was fully dissolved. ABT-737 or vehicle was
administered daily for 21 days via intraperitoneal (i.p.) injection. A
stock solution of TMZ dissolved in DMSO was diluted in normal
saline (0.9%) each day prior to use, and TMZ or normal saline
vehicle was administered on days 1–5 and 11–15 via i.p. injection.
On days when both drugs were administered, TMZ was
administered at least 5 h prior to ABT-737.
Statistical analysis
The anti-proliferative effects from MTS assays were entered into
Calcusyn software (Biosoft, Ferguson, MO) to calculate IC50 values
for individual drugs and to determine whether the treatment
combinations had synergistic, additive, or antagonistic effects using
the Chou-Talalay method [30]. When the CI value is less than 1, it
indicates synergistic effects, and the lower the CI, the stronger the
Figure 5. p53 is not necessary for synergy between TMZ and ABT-737. MTS assays of RPMI-7951 (a p53-null line) with varying doses of TMZ
(A) or nutlin-3 (B) with or without 3.3 mM ABT-737. (C) Annexin V assays of RPMI-7951 cells treated with or without 400 mM TMZ and 3.3 mM ABT-737
(left) or 4 mM nutlin-3 and 3.3 mM ABT-737 (right). (D) Immunoblots of cell lysates from the Annexin V experiments shown in C show Noxa induction
in TMZ/ABT-737-treated cells but not in nutlin-3/ABT-737-treated cells. Relative ratios of Noxa to tubulin are shown below, with each value
normalized to the control. (E) Immunoblots of several melanoma cell lines show that p53 is undetectable in RPMI-7951 cells.
doi:10.1371/journal.pone.0024294.g005
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was used to compare individual tumor doubling rates. Log-rank
(Mantel-Cox) tests were used to compare Kaplan-Meier curves with
the program GraphPad Prism 5 (GraphPad Software, San Diego,
CA), and p-values of 0.05 and below were considered significant.
Supporting Information
Figure S1 Time-course experiments for cells treated
with TMZ with or without ABT-737. MTS assays were
performed for each 24 h time-point between 48 and 120 h for
1205Lu (A, B) and A375 (C, D) cell lines. Experiments included
varying concentrations (mM) of TMZ alone (A, C) or varying
concentrations of TMZ with 3.3 mM of ABT-737 (B, D). Results
for each cell line are normalized to DMSO controls (0 TMZ) set at
100% for each time-point, and error bars represent +/- SE of 3
measurements.
(PDF)
Figure S2 Fraction affected vs. Combination Index (CI)
for melanoma cells treated with TMZ and ABT-737.
1205Lu cells (A) or A375 cells (B) were treated with escalating doses
of TMZ (50, 100, 200, 400 mM) and ABT-737 (0.94, 1.88, 3.75, 7.5
mM) for 72 h and then subjected to MTS assays. CI plots were
generated using Calcusyn software according to the Chou-Talalay
method, and algebraic simulations are shown +/- estimated s.d.
(PDF)
Table S1 IC50 values (mM) for two melanoma cell lines
for two drugs with 72 h treatment times. Values in
parentheses represent the 95% confidence interval.
(PDF)
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Figure 6. TMZ and ABT-737 reduce tumor growth in a mouse xenograft model. (A) Tumor growth curves. (B) Kaplan-Meier curves for
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